Edesa Biotech, Inc. (EDSA) |
| 1.36 -0.15 (-9.93%) 02-25 16:00 |
| Open: | 1.38 |
| High: | 1.42 |
| Low: | 1.2 |
| Volume: | 4,053,457 |
| Market Cap: | 11(M) |
| PE Ratio: | -1.27 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.08 |
| Resistance 1: | 1.78 |
| Pivot price: | 1.07 |
| Support 1: | 1.12 |
| Support 2: | 0.72 |
| 52w High: | 2.95 |
| 52w Low: | 0.72 |
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Financials
| EPS | -1.070 |
| Book Value | 0.560 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -55.3 |
| Return on Equity (ttm) | -96.4 |
Company news
Tue, 24 Feb 2026
Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com
Tue, 24 Feb 2026
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com
Tue, 24 Feb 2026
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - Bitget
Tue, 24 Feb 2026
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 3 Study of Paridiprubart for ARDS and Related Conditions - Quiver Quantitative
Tue, 24 Feb 2026
Edesa drug cuts death risk to 24% in Phase 3 ARDS trial - Stock Titan
Fri, 13 Feb 2026
Edesa Biotech (Nasdaq: EDSA) widens loss as R&D spending climbs - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
